Prevalence of Sickle cell disease, Sickle cell trait and HBS-beta-thalassemia in India: A systematic review and Meta-analysis

IF 2.3 Q2 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

Clinical Epidemiology and Global Health Pub Date : 2024-07-01 DOI:10.1016/j.cegh.2024.101678

Priyanka Rao , Elstin Anbu Raj , Senthilkumar Natesan , Nachiket Gudi

{"title":"Prevalence of Sickle cell disease, Sickle cell trait and HBS-beta-thalassemia in India: A systematic review and Meta-analysis","authors":"Priyanka Rao , Elstin Anbu Raj , Senthilkumar Natesan , Nachiket Gudi","doi":"10.1016/j.cegh.2024.101678","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Sickle Cell Disease (SCD) is a common inherited disease in India. However, more aggregate data regarding the burden and distribution of SCD in India is required.</p></div><div><h3>Methods</h3><p>A search was conducted in five electronic databases between 2000 and 2023. The quality appraisal was performed using the JBI Critical Appraisal Tool for prevalence studies. The review is reported according to the PRISMA guidelines.</p></div><div><h3>Results</h3><p>87 studies were included in this systematic review. The prevalence of SCD, Sickle cell trait (SCT), and HBS-beta-thalassemia was estimated to be 1.17% (95% CI:0.79%–1.75%), 5.9% (95% CI:3.8%–8.88%) and 0.37% (95% CI:0.17%–0.83%) respectively. Madhya Pradesh, Chhattisgarh, and Maharashtra have a high prevalence of SCD and SCT. The burden is higher among the tribal communities of India.</p></div><div><h3>Conclusion</h3><p>Prioritizing the management of SCD in India through targeted screening among communities of at-risk couples and newborns, and pre-marital counseling and raising awareness can assist in reducing the disease burden.</p></div>","PeriodicalId":46404,"journal":{"name":"Clinical Epidemiology and Global Health","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S221339842400174X/pdfft?md5=55c1a25c3b5ea0e63e601c9514494416&pid=1-s2.0-S221339842400174X-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Epidemiology and Global Health","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S221339842400174X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Sickle Cell Disease (SCD) is a common inherited disease in India. However, more aggregate data regarding the burden and distribution of SCD in India is required.

Methods

A search was conducted in five electronic databases between 2000 and 2023. The quality appraisal was performed using the JBI Critical Appraisal Tool for prevalence studies. The review is reported according to the PRISMA guidelines.

Results

87 studies were included in this systematic review. The prevalence of SCD, Sickle cell trait (SCT), and HBS-beta-thalassemia was estimated to be 1.17% (95% CI:0.79%–1.75%), 5.9% (95% CI:3.8%–8.88%) and 0.37% (95% CI:0.17%–0.83%) respectively. Madhya Pradesh, Chhattisgarh, and Maharashtra have a high prevalence of SCD and SCT. The burden is higher among the tribal communities of India.

Conclusion

Prioritizing the management of SCD in India through targeted screening among communities of at-risk couples and newborns, and pre-marital counseling and raising awareness can assist in reducing the disease burden.

查看原文本刊更多论文

印度镰状细胞病、镰状细胞性状和 HBS-β-地中海贫血症的患病率：系统回顾和元分析

背景镰状细胞病（SCD）是印度常见的遗传性疾病。方法在 2000 年至 2023 年期间的五个电子数据库中进行了检索。采用 JBI 流行病研究关键评估工具进行质量评估。结果87项研究被纳入本系统综述。据估计，SCD、镰状细胞性状（SCT）和 HBS-β-地中海贫血的患病率分别为 1.17% (95% CI:0.79%-1.75%), 5.9% (95% CI:3.8%-8.88%) 和 0.37% (95% CI:0.17%-0.83%).中央邦、恰蒂斯加尔邦和马哈拉施特拉邦的 SCD 和 SCT 患病率较高。结论在印度，通过对高危夫妇和新生儿社区进行有针对性的筛查、婚前咨询和提高认识来优先管理 SCD，有助于减少疾病负担。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Epidemiology and Global Health PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-

CiteScore

4.60

自引率

7.70%

发文量

218

审稿时长

66 days

期刊介绍： Clinical Epidemiology and Global Health (CEGH) is a multidisciplinary journal and it is published four times (March, June, September, December) a year. The mandate of CEGH is to promote articles on clinical epidemiology with focus on developing countries in the context of global health. We also accept articles from other countries. It publishes original research work across all disciplines of medicine and allied sciences, related to clinical epidemiology and global health. The journal publishes Original articles, Review articles, Evidence Summaries, Letters to the Editor. All articles published in CEGH are peer-reviewed and published online for immediate access and citation.

文献相关原料

公司名称	产品信息	采购帮参考价格